Cannabis and Substance Use: Peer-Reviewed Research Consensus

47 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis and substance use includes 47 peer-reviewed studies spanning 2025–2026. Of these, 7 provide strong evidence, including 0 meta-analyses and 0 randomized controlled trials. Key findings with strong support include: in 526 young adults tracked through emerging adulthood, cannabis use increases predicted more binge drinking at ages 18–21 but less binge drinking by ages 24–25, revealing an age-dependent relationship, and among 3,544 young adults in the path study, moderate-to-severe pain predicted starting concurrent alcohol and cannabis use — a particularly risky pattern associated with heavier use and more harm. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

In 526 young adults tracked through emerging adulthood, cannabis use increases predicted more binge drinking at ages 18–21 but less binge drinking by ages 24–25, revealing an age-dependent relationship

Moderate Evidence
7 studies|Based on limited number of strong-evidence studies.

Among 3,544 young adults in the PATH study, moderate-to-severe pain predicted starting concurrent alcohol and cannabis use — a particularly risky pattern associated with heavier use and more harm

Moderate Evidence
7 studies|Based on limited number of strong-evidence studies.

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

Large prospective study of 2,449 trauma survivors found pre-trauma insomnia predicted heavier cannabis and alcohol use 8 weeks later, partly through early PTSD symptoms

Moderate Evidence
13 studies|Pre-trauma insomnia was assessed retrospectively during the ED visit, introducing potential recall bias. Cannabis use was self-reported. Only 8-week follow-up, so longer-term patterns are unknown. Obs

Systematic review of 50 studies found anxiety sensitivity linked to coping-motivated cannabis use and problematic use patterns, but not to whether or how often someone uses cannabis

Moderate Evidence
13 studies|Qualitative synthesis only, no meta-analytic effect sizes. Most included studies were cross-sectional. Publication bias not formally assessed. Heterogeneity in how anxiety sensitivity and cannabis use

Secondary analysis of a randomized trial found people with opioid use disorder receiving buprenorphine were 39% less likely to use cannabis than those receiving naltrexone

Moderate Evidence
13 studies|Secondary analysis of a trial not designed for this outcome. Borderline statistical significance. Cannabis use was self-reported. Mechanisms for the differential effect are unknown. May not generalize

Analysis of 496 cannabis users in São Paulo identified four distinct profiles, with about 30% in high-risk categories characterized by early onset, frequent use, and polydrug patterns

Moderate Evidence
13 studies|Cross-sectional design limits causal inference. Self-reported substance use. São Paulo sample may not represent all of Brazil. Latent class analysis findings are sample-dependent and may not replicate

What We Still Don't Know

  • Only 0 randomized controlled trials exist out of 47 studies — most evidence is observational or from reviews.
  • No meta-analyses have been published on this specific topic, limiting the ability to draw pooled quantitative conclusions.
  • Sex-specific differences in this area remain understudied.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Observational & Cohort(Tier 3-4)
35 (74%)
Reviews & Scoping(Tier 4)
2 (4%)
Other
10 (21%)

Key Studies

The most impactful research in this area.

8% of Americans Co-Use Tobacco and Cannabis — Here's How They Do It

Co-use of tobacco and cannabis compounds health risks (as shown by RTHC-08179), and understanding how people combine these substances is essential for prevention. The age-based differences in administration routes suggest different intervention approaches are needed for different generations.

2026

Earlier Cannabis Use Start Predicts More Substance Problems Through Adolescence

This birth-to-adulthood study maps the developmental chain from early childhood risk factors to adolescent cannabis initiation to adult substance problems, identifying multiple intervention points.

2026

Cannabis Legalization Drives Up Tobacco-Cannabis Co-Use While Reducing Tobacco-Only Use

While legalization reduces tobacco-only use, the simultaneous increase in tobacco-cannabis co-use — which combines the health risks of both substances — represents an unintended consequence that public health responses must address.

2026

Transgender and Questioning Youth Show Higher Cannabis Curiosity and Use by Age 14

This is one of the first studies to use a multidimensional gender construct to understand substance use risk in pre-adolescents, revealing that gender-diverse youth need targeted prevention before traditional intervention ages.

2026

Anxiety Sensitivity Linked to Coping-Motivated Cannabis Use, Not Overall Use Frequency

Understanding why some people develop problematic cannabis use while others do not is key for prevention. This review identifies a specific psychological trait that predicts not whether someone uses cannabis, but why they use it and whether that use becomes problematic.

2025

Cannabis and Mood Disorders in Teens Are Closely Intertwined and Mutually Reinforcing

Adolescence is a period of active brain development when both mood disorders and cannabis use commonly emerge. Understanding their interaction is critical for clinicians treating either condition in this age group.

2025

Research Timeline

How our understanding of this topic has evolved.

2020–present

47 studies published. Includes 7 strong-evidence studies.

About This Consensus

This consensus synthesizes 47 peer-reviewed studies: 35 observational studies (74%), 2 reviews (4%), 10 other study types (21%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 47 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.